Correction to: Real-World Treatment Patterns, Adverse Events, Resource Use, and Costs Among Commercially Insured, Younger Patients with Chronic Lymphocytic Leukemia in the USA: A Retrospective Cohort Study

Shaum M Kabadi; Aimee Near; Keiko Wada; Chakkarin Burudpakdee

doi:10.1007/s12325-020-01400-3

Correction to: Real-World Treatment Patterns, Adverse Events, Resource Use, and Costs Among Commercially Insured, Younger Patients with Chronic Lymphocytic Leukemia in the USA: A Retrospective Cohort Study

Adv Ther. 2020 Jul;37(7):3149. doi: 10.1007/s12325-020-01400-3.

Authors

Shaum M Kabadi¹, Aimee Near², Keiko Wada³, Chakkarin Burudpakdee²

Affiliations

¹ AstraZeneca, Gaithersburg, MD, USA.
² IQVIA, Falls Church, VA, USA.
³ IQVIA, Falls Church, VA, USA. [email protected].

PMID: 32535853
DOI: 10.1007/s12325-020-01400-3

Abstract

In the original article, it has been noticed that the abbreviation ''CLL'' is incorrectly published throughout the paper as the abbreviation "CCL". The correct abbreviation is "CLL".

Publication types

Published Erratum